The limited impact of treatments for COVID-19 has stimulated several phase 1 clinical trials of whole-lung low-dose radiation therapy (LDRT; 0.3–1.5 Gy) that are now progressing to phase 2 randomized trials worldwide. This novel but unconventional use of radiation to treat COVID-19 prompted the National Cancer Institute, National Council on Radiation Protection and Measurements and National Institute of Allergy and Infectious Diseases to convene a workshop involving a diverse group of experts in radiation oncology, radiobiology, virology, immunology, radiation protection and public health policy. The workshop was held to discuss the mechanistic underpinnings, rationale, and preclinical and emerging clinical studies, and to develop a general framework for use in clinical studies. Without refuting or endorsing LDRT as a treatment for COVID-19, the purpose of the workshop and this review is to provide guidance to clinicians and researchers who plan to conduct preclinical and clinical studies, given the limited available evidence on its safety and efficacy.

COVID-19 治疗的有限影响刺激了多项全肺低剂量放射治疗（LDRT；0.3-1.5 Gy）的 1 期临床试验，这些试验目前正在全球范围内进展到 2 期随机试验。这种新颖但非传统的放射治疗方法促使国家癌症研究所、国家辐射防护和测量委员会以及国家过敏和传染病研究所召开了一次研讨会，由放射肿瘤学、放射生物学、病毒学领域的不同专家组成。 、免疫学、辐射防护和公共卫生政策。举办研讨会的目的是讨论机制基础、基本原理以及临床前和新兴临床研究，并制定用于临床研究的总体框架。在不反驳或认可 LDRT 作为 COVID-19 治疗方法的情况下，研讨会和本次综述的目的是为计划进行临床前和临床研究的临床医生和研究人员提供指导，因为有关其安全性和有效性的现有证据有限。